Navigation Links
Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

- Presentation to Be Webcast Live on Company's Website -

TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-Astoria Hotel in New York City.

Paul J. Lytle, Peregrine's chief financial officer, will provide a review of recent corporate developments.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information abo
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
2. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
3. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 21, 2015 ... announced the addition of the "Analysis of ... to their offering. Globally, flow cytometry ... immuno-phenotyping, cell proliferation, cancer, and stem cells. But ... applications primarily because of demand from underdeveloped nations ...
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private ... to local area veterinarians. , The tour and course will be given every Wednesday ... at VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that ... its recent Annual General Meeting. The six-member Board consists ... Jim Heppell, Mr. Amos Michelson, Dr. Bradley Popovich and ... molecular diagnostics, commercialization and personalized medicine experience that is ...
... ... Pilest was recently selected by Solta Medical (parent company of Fraxel and Thermage) as ... more profound improvements when patients have undergone both procedures within a close time span. ... the cosmetic laser industry. , ...
Cached Biology Technology:EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2Sirius Genomics Announces 2009 Board of Directors 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 3
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... have identified the genetic signature of respiratory syncytial virus (RSV), ... work is a key step toward a better understanding of ... of a vaccine and a tool that could allow physicians ... develop. The study, from a team at The Research Institute ...
... like hantaviruses and arenaviruses are simple, but resourceful, and ... generating a mere four proteins compared to humans, thousands, ... replication dirty work, facilitating infection, plus a high mortality ... targeted, may stop these deadly viruses in their tracks. ...
... Have you ever wondered why some ice cubes are as ... savory breads? Celebrity chef Alton Brown answers these questions in ... episode. The video is available now on http://www.BytesizeScience.com . ... says. "So if you understand science, at least some of ...
Cached Biology News:Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Bleeding symptom leads scientists to intracellular trafficker's role in virus propagation 2Bleeding symptom leads scientists to intracellular trafficker's role in virus propagation 3
... with FAM-Labeled Substrate (green fluorescence; Ex=488 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
Request Info...
... The Multiple Species Tissue Array (MSTA) slides ... different cells and tissues from multiple species. ... on each MSTA slide which can then be ... staining, immunohistochemistry, or in situ hybridization. ...
... The Gene Pulser Xcell eukaryotic ... 50-60 Hz, is used for ... system includes the main unit, ... microfarad range) or square-wave pulses, ...
Biology Products: